234080-72-9

Upstream product

• 80518-57-6 ethyl 4-(piperazin-1-yl)benzoate 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 233283-14-2 ethyl 4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzoate 
• 234081-73-3 4-{4-(Pyrimidin-2-yl)-piperazin-1-yl}-benzoic acid 
• 156185-89-6 tert-butyl (2S)-N-benzenesulfonyl-2,3-diaminopropionate 

Downstream Products

• 234081-18-6 2-(benzenesulfonyl-methyl-amino)-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid tert-butyl ester 
• 234081-19-7 2-(N-benzenesulfonyl-N-methylamino)-3-[4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoylamino]propionic acid 
• 891853-86-4 2-{benzenesulfonyl-[12-(benzenesulfonyl-{1-tert-butoxycarbonyl-2-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-ethyl}-amino)-dodecyl]-amino}-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid tert-butyl ester 
• 891853-94-4 (S)-2-{Benzenesulfonyl-[12-(benzenesulfonyl-{(S)-1-carboxy-2-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-ethyl}-amino)-dodecyl]-amino}-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid 
• 911289-62-8 2-[benzenesulfonyl-(12-methanesulfonyloxy-dodecyl)-amino]-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid tert-butyl ester 
• 891853-90-0 2-[benzenesulfonyl-(12-iodo-dodecyl)-amino]-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid tert-butyl ester 
• 891853-88-6 2-[benzenesulfonyl-(12-hydroxy-dodecyl)-amino]-3-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-benzoylamino]-propionic acid tert-butyl ester 
• 234080-73-0 (2S)-benzenesulfonylamino-3-[4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzoylamino]-propionic acid 

Relevant academic research and scientific papers

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/ αIIbβ3 dual antagonistic activity

In order to generate novel compounds with integrin α vβ3-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective αIIbβ3 antagonists, replacement of piperazine with piperidine furnished a potent αvβ3/ αIIbβ3 dual antagonist. Structure-activity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists.